Table 1.

Characteristics of Patients

Characteristic (n=75)
	number of patients (percent)
Male	51 (68)
Mean age - years	54·3±11·5
ECOG* performance status
0	43 (57)
1	30 (40)
2	2 (3)
Sunitinib Treatment
Median weeks on-study	33·6
Range (weeks)	3·3-112·4
Dosage
(mg; weeks on drug/weeks off drug)
25; 2/2	6 (8)
50; 2/2	23 (31)
50; 2/1	6 (8)
75; 2/2	4 (5)
50; 4/2	36 (48)
Prior Cardiac History
CAD	4 (5)
CHF	0 (0)
Baseline Cardiac Risk Factors
HTN	22 (29)
Smoking	20 (27)
Diabetes	8 (11)
Hyperlipidemia	8 (11)
Cardiac Medications at Baseline
ACE inhibitor	6 (8)
Beta blocker	10 (13)
Statin	5 (7)
Prior Thyroid Disease
Hypothyroidism†	9 (12)
Prior Chemotherapy
Anthracycline	15 (20)
Imatinib	75 (100)

^*ECOG = Eastern Cooperative Oncology Group; 0 = Fully active, able to carry on all pre-disease performance without restriction, 1= Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2 = Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours.

^†History of hypothyroidism or elevated TSH at baseline.